Lacerta Therapeutics
Ryan M Spengler has a diverse work experience spanning over several years. Ryan M'smost recent role is as an Assistant Director of Bioinformatic Sciences at Lacerta Therapeutics since February 2022. Prior to that, they worked as a Bioinformatics Consultant at the same company from June 2021 to February 2022.
Before joining Lacerta Therapeutics, Ryan worked as an Assistant Scientist at the University of Wisconsin-Madison from November 2019 to February 2022. In this role, they likely contributed to scientific research and investigations.
Ryan M also served as a Postdoctoral Research Fellow at the University of Michigan from September 2015 to November 2019, and as a Post-Doctoral Fellow at the University of Iowa from March 2013 to September 2015. During these positions, Ryan likely conducted research and contributed to scholarly publications.
Ryan's earlier experience includes working as a Graduate Research Assistant at the University of Iowa from June 2007 to March 2013. Additionally, they worked at Six Flags Great America as a Rides Supervisor from 2004 to 2005, and as a Rides Lead from 2001 to 2003.
Overall, Ryan M Spengler has a strong background in bioinformatics, research, and leadership roles within the academic and biotech industries.
Ryan M Spengler earned a Bachelor of Arts (BA) degree in Biology, General from Augustana College, where they studied from 2003 to 2007. Afterward, they pursued further education at the University of Iowa, where they obtained a Doctor of Philosophy (PhD) degree in Cell/Cellular and Molecular Biology, from 2007 to 2013.
This person is not in any offices
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.